Can You Advertise BPC-157, and What Does the FDA Status Mean?

What is BPC-157's FDA status in 2026?

Compounding pharmacies may use bulk drug substances only in defined circumstances, and FDA evaluates substances nominated for that use. Under its interim policy, Category 2 holds substances that may present significant safety risks, and BPC-157 sat there until 2026. MedScale works with telehealth brands and clinics, and BPC-157's status is usually the first thing a peptide clinic asks about when it asks about ads.

• April 22, 2026: FDA's Category 2 page lists BPC-157 under "Bulk drug substances nominated but withdrawn", which it describes as substances previously in Category 2 that were withdrawn by the nominators. The entry still notes that compounded drugs containing BPC-157 may pose a risk for immunogenicity for certain routes of administration.
• July 23-24, 2026: FDA's Pharmacy Compounding Advisory Committee discussed BPC-157 for the 503A bulks list and voted 8 to 6 to recommend it, along with KPV, TB-500, MOTS-c, Epitalon and Semax.
• September 22, 2026: LegitScript wrote that BPC-157 is not currently eligible for compounding, sale or use under the US framework, and that a certified business may not offer, promote or advertise it, directly or through a partner. Content that encourages its use counts as promotion whether or not the business sells it.
• October 14, 2026: FDA sent a notice titled "Interim Access Policy for Compounding Using Certain Peptides" to the White House Office of Information and Regulatory Affairs for review. Its text is not public.
• October 23, 2026: the committee's vote remains a recommendation that does not bind FDA. BPC-157 is not on the 503A bulks list and is not FDA-approved, so product ads stay closed on Meta, Google and TikTok.
• October 30, 2026: HHS published its Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Federal Register 2026-22192). HHS says it "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A," which lists BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The same notice says compounded drugs "are not FDA-approved" and that the policy "is not binding on HHS or the public." Written comments can be submitted until November 13, 2026, two weeks after publication.
• November 2, 2026: LegitScript updated its certification review. It says offering one of the six peptides "should not, by itself, prevent a merchant from achieving certification" when the offering meets HHS's conditions, which include a 503A pharmacy or physician compounder, a single active ingredient, an FDA 510(k)-cleared syringe as the only device, and the label "This is a compounded drug product. Not for resale."
• November 3, 2026: BPC-157 is still not FDA-approved and not on the 503A bulks list, and Meta's drugs policy, Google's unapproved substances policy and TikTok's healthcare policy show no change. MedScale still runs the consult, not the compound.

Withdrawal from Category 2 is not a clearance. BPC-157 is not FDA-approved, is not on the 503A bulks list, and a non-binding vote changes neither fact. Specific compounding questions belong with regulatory counsel; this page is about advertising.